[go: up one dir, main page]

PL363116A1 - Use of csaids in rhinovirus infection - Google Patents

Use of csaids in rhinovirus infection

Info

Publication number
PL363116A1
PL363116A1 PL00363116A PL36311600A PL363116A1 PL 363116 A1 PL363116 A1 PL 363116A1 PL 00363116 A PL00363116 A PL 00363116A PL 36311600 A PL36311600 A PL 36311600A PL 363116 A1 PL363116 A1 PL 363116A1
Authority
PL
Poland
Prior art keywords
csaids
rhinovirus infection
rhinovirus
infection
Prior art date
Application number
PL00363116A
Other languages
English (en)
Polish (pl)
Inventor
Susan B. Dillon
Sandra D. Griego
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of PL363116A1 publication Critical patent/PL363116A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL00363116A 1999-09-17 2000-09-15 Use of csaids in rhinovirus infection PL363116A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15449499P 1999-09-17 1999-09-17

Publications (1)

Publication Number Publication Date
PL363116A1 true PL363116A1 (en) 2004-11-15

Family

ID=22551566

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00363116A PL363116A1 (en) 1999-09-17 2000-09-15 Use of csaids in rhinovirus infection

Country Status (17)

Country Link
EP (1) EP1223924A4 (fr)
JP (1) JP2003516314A (fr)
KR (1) KR20020032591A (fr)
CN (1) CN1382044A (fr)
AR (1) AR025691A1 (fr)
AU (1) AU7584500A (fr)
BR (1) BR0014041A (fr)
CA (1) CA2385722A1 (fr)
CO (1) CO5200855A1 (fr)
CZ (1) CZ2002939A3 (fr)
HU (1) HUP0204333A3 (fr)
IL (1) IL148329A0 (fr)
NO (1) NO20021301L (fr)
PL (1) PL363116A1 (fr)
TR (1) TR200200673T2 (fr)
WO (1) WO2001019322A2 (fr)
ZA (1) ZA200202060B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
ATE258055T1 (de) 1998-11-04 2004-02-15 Smithkline Beecham Corp Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
ATE281439T1 (de) 1999-11-23 2004-11-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
ATE305787T1 (de) 1999-11-23 2005-10-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
JP2003514900A (ja) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
JP2004530648A (ja) * 2000-10-19 2004-10-07 スミスクライン・ビーチャム・コーポレイション 炎症により促進される咳の治療のためのｐ３８阻害剤の使用
CA2426654C (fr) 2000-10-23 2010-12-21 Smithkline Beecham Corporation Nouveaux composes
AU2003230692A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of map kinase inhibitors
BR0309009A (pt) * 2002-04-05 2005-03-22 Boehringer Ingelheim Pharma Método para o tratamento de hipersecreção de muco
AU2003245989A1 (en) * 2002-07-09 2004-01-23 Boehringer Ingelheim Pharma Gmbh And Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
JP4593953B2 (ja) * 2004-03-30 2010-12-08 杏林製薬株式会社 ライノウイルス感染症の予防薬
CA2575932A1 (fr) * 2004-08-04 2006-02-16 Schering Corporation Formulations pharmaceutiques
MY145343A (en) 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
DK2276505T3 (da) * 2008-03-20 2013-11-25 Krister Tano Næsespray eller næsedråber til behandling af forkølelse
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
EP2477642A4 (fr) * 2009-09-17 2013-03-13 Mutual Pharmaceutical Co Procédé de traitement de l'asthme avec des agents antiviraux
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods
GB201010193D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Medicinal use
US11389663B2 (en) 2011-04-01 2022-07-19 Bioregentech, Inc. Laser assisted wound healing protocol and system
US11730760B2 (en) 2011-04-01 2023-08-22 The Bioregentech Institute, Inc. Laser assisted wound healing protocol and system
GB201611712D0 (en) 2016-07-02 2016-08-17 Hvivo Services Ltd Methods and compounds for the treatment or prevention of severe or persistent influenza
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3078232A1 (fr) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Utilisation d'inhibiteurs de p38 pour reduire l'expression de dux4
GB201721793D0 (en) * 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza
WO2021216754A1 (fr) * 2020-04-21 2021-10-28 Spring Discovery, Inc. Utilisation d'inhibiteurs de p38 mapk pour la prévention et le traitement du vieillissement et de troubles liés au vieillissement et pour renforcer un système immunitaire

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927216A (en) * 1971-06-01 1975-12-16 Icn Pharmaceuticals 1,2,4-Triazol E-3-carboxamides for inhibiting virus infections
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
EP1140083A4 (fr) * 1999-01-08 2004-01-02 Smithkline Beecham Corp Nouveaux composes

Also Published As

Publication number Publication date
ZA200202060B (en) 2003-05-28
HUP0204333A3 (en) 2004-07-28
KR20020032591A (ko) 2002-05-03
BR0014041A (pt) 2003-07-15
WO2001019322A2 (fr) 2001-03-22
TR200200673T2 (tr) 2002-12-23
EP1223924A4 (fr) 2004-07-14
IL148329A0 (en) 2002-09-12
JP2003516314A (ja) 2003-05-13
NO20021301D0 (no) 2002-03-15
NO20021301L (no) 2002-05-16
CZ2002939A3 (cs) 2002-11-13
AU7584500A (en) 2001-04-17
WO2001019322A3 (fr) 2001-10-04
CN1382044A (zh) 2002-11-27
AR025691A1 (es) 2002-12-11
CA2385722A1 (fr) 2001-03-22
EP1223924A2 (fr) 2002-07-24
CO5200855A1 (es) 2002-09-27
HUP0204333A2 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
HUP0204333A3 (en) Use of csaids in rhinovirus infection
GB9915414D0 (en) Medical use
GB0004167D0 (en) 1-piperidinyl-propan-2-ol derivatives and their use as therapeutic agents
PL352330A1 (en) Derivatives of pyridopyranoazepine, making of same and use of same in therapy
IL147503A0 (en) Oxazolidinone compounds and methods of preparation and use thereof
AU4289100A (en) Dihydropyrimidines and their use in the treatment of hepatitis
HU0001396D0 (en) 3-amino-3-arylpropan-1-al derivatives and their use
PL352333A1 (en) Dihydrobenzodiazepines and use of same in treatment of dislipidemia
GB9907965D0 (en) Medical use
EP1161451A4 (fr) Endokine alpha humain et methodes d'utilisation
GB9929318D0 (en) Macrocyclic compounds and their use
HK1048936A (zh) Csaids在鼻病毒感染中的用途
PL350963A1 (en) Use of arylalkanoylpyridazines
GB9925379D0 (en) Medical use
AU4116500A (en) The use of alpha lipoic acid in the antimetastatic treatment
GB9922825D0 (en) Medical use
AU3554800A (en) Use of porphyrin derivatives in aquariums
GB9911238D0 (en) Therapeutic use
AU2001223910A1 (en) Interferon-alpha use in the treatment of ewing's family of tumors
GB9929581D0 (en) Comjpositions and their use
GB9905315D0 (en) Therapy and use of compounds in therapy
GB9905307D0 (en) Therapy and use of compounds in therapy
GB0022210D0 (en) Treatment of infection in animals
GB0012401D0 (en) Treatment of infection in animals
GB9901904D0 (en) RTherapeutic use of human pheramones

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)